Blood Volume Analysis Using The BVA-100: Interview with Michael Feldschuh, Daxor CEO

50


Daxor Corporation, a company based in New York, has developed the BVA-100, a blood volume analysis test. The test is the first to be FDA approved for the quantification of blood volume and composition. Following the injection of a radio-labeled tracer, a blood sample is obtained from the patient and analyzed. The entire process takes less than one hour and provides clinicians with information on total blood volume, red blood cell volume, and plasma volume.

Blood volume adjustments are important in a wide variety of disease states, but in many cases clinicians have to rely on indirect measurements of blood volume, meaning that they do not have completely accurate information with which to make treatment decisions. The BVA-100 aims to provide an objective and accurate measurement of blood volume to take the guesswork out of making blood volume adjustments.

The test has proven to be useful during the current COVID-19 pandemic, with patients on ventilation requiring frequent fluid adjustments, such as blood transfusions.

See a video about Daxor’s technology and blood volume analysis below:

Medgadget had the opportunity to talk to Michael Feldschuh, CEO of Daxor, about this technology and its role during the pandemic.

Conn Hastings, Medgadget: Please give us an overview of the importance of blood volume analysis in terms of diagnostics and clinical decision making.

Michael Feldschuh, Daxor: Blood Volume
Analysis (BVA) is important because a healthy blood volume is a biological
imperative central to tissue perfusion — it is vital to all organ systems and
cells in the body as blood contains red cells to carry oxygen, important
proteins, and plasma as a conduit. The importance of ensuring that patients are
at an optimal blood volume is known to all clinicians and interventions which
correct volume derangements are routinely made and critical to organ and tissue
health and survival. The challenge has been how to measure the optimal blood
volume and to know that a patient is at “euvolemia” — ensuring adequate tissue
perfusion and homeostatic response.

Heterogeneity
of volume status is common in many conditions and challenging to manage without
an accurate diagnostic that directly measures blood volume versus an accurate
patient-specific norm. Patients with identical clinical symptoms often have
different etiologies and underlying blood volume derangements, increasing the
risk that iatrogenic interventions will be harmful (for example giving
vasopressors when more fluid would be appropriate or over-diuresing a patient
which can lead to acute kidney injury). The BVA-100 test reveals this
variability permitting precise individualized therapeutic strategies instead of
a “one-size-fits-all” approach and ends the debate at the bedside of the
patient’s volume status.

Medgadget: What conditions and diseases can affect blood volume? Can returning blood volumes to ideal levels help in treating such conditions?

Michael Feldschuh: Treating a patient’s blood volume and its composition is central to a
broad range of chronic and acute indications including but not limited to
congestive heart failure, sepsis, blood loss due to trauma or surgical
procedures, hypertension, renal failure and syncope. Maintaining a normal blood
volume is like “walking a tightrope”, too much or too little can have serious
consequences.

Fluid management is a significant challenge for patients in the ICU. A
randomized control trial (RCT) on volume management guided by the BVA-100 test
was conducted on patients in the SICU at a leading trauma center. The results
showed a 66% reduction in mortality versus the prior standard of care when BVA
was used to guide treatment. Ventilator use and length of stay also trended
down as well.

Heart failure also represents one of the largest areas of healthcare
spending and one of the most significant treatment challenges for approximately
6 million US patients. In a landmark peer-reviewed study published in the Journal of the
American College of Cardiology – Heart Failure, BVA guided care was proven to reduce heart failure
30-day mortality by 82%, 30-day readmissions by 56%, and 1-year
mortality by 86%. This study highlights the
value of our technology and its potential to improve heart failure outcomes.

There have been dozens of peer-reviewed studies that have established
the value of the BVA-100 test for clinical use, confirming that accurate blood
volume measurement leads to better informed physicians, better treatment
strategies, and improves patient outcomes and resource utilization.

Medgadget: What are the problems with surrogate measures of blood volume that clinicians sometimes use in the absence of a device such as the BVA-100?

Michael Feldschuh: Physicians predominantly rely on
clinical assessment and a range of surrogate or indirect measures (i.e.
hemoglobin, hematocrit, pressure measures, hemodynamics, ultrasound, levels of
brain natriuretic peptide, etc.) to estimate patient blood volume in the
absence of the direct BVA-100 test. A multitude of studies have shown these
indirect tests for assessing volume are vastly inferior in that they lack
specificity and sensitivity compared with the BVA-100 test. Treatment goals for
volume assessment can be a high-stakes guessing game without accurate knowledge
of both the patient’s actual and ideal total blood volume. The BVA-100 provides
objective and actionable data and ends the debate at the bedside so the
patient’s optimal blood volume can be restored.

Medgadget: How does the BVA-100 test work? Is it easy to use?

Michael Feldschuh: The BVA-100 test is a simple
blood test with results available within 1-hour. The test uses a radiolabeled
tracer that is injected into the patient at the bedside, blood is drawn from
the patient, and a precise calculation of the patient’s volume derangement and
insights into the capillary leak is determined by the dilution of the tracer. The
“indicator dilution” method is considered the “gold standard” for this
measurement. This is why the BVA-100 test has generated over 45,000 test
results, and has been used in over 100 studies, drug trials, and case studies
since its launch.

Medgadget: How are blood volume measurements relevant to COVID-19 patient outcomes and treatment?

Michael Feldschuh: COVID-19 patients with
ARDS/respiratory distress end up on ventilators and typically need fluid
adjustments, which can mean more or less supportive fluids such as saline or
even blood transfusions. There is no one adjustment they all need —
circulatory support needs to be individualized. The benefit of the BVA-100 test
is it enables care teams to immediately adjust patients to their optimal blood
volume by allowing them to see if a patient is too under or over resuscitated. Correct
fluid adjustments ensure circulatory integrity and optimal tissue perfusion.

Medgadget: How has the BVA-100 test been used to date during the COVID-19 pandemic?

Michael Feldschuh: Institutions have been using
and collecting data on BVA guided care COVID-19 patients to assist with fluid
management. In a randomized control trial (RCT) conducted at a Level-1 trauma
center on patients suffering predominantly from ARDS/sepsis/septic
shock/hemorrhagic shock patients who received BVA guided care showed
significant benefits including 66% lower mortality, days on ventilators, and
ICU length of stay. This study group had a similar patient profile as those
with COVID-19 in the ICU in that they have significant challenges in
maintaining blood volume and endothelial damage.

A RCT on COVID-19 patients is not available yet, but clinical usage so far has shown the BVA-100 test provides significant insights into volume derangements and capillary permeability; the albumin transudation rate which is a unique metric of the BVA-100 test. It is an indicator of the rate at which fluids may be escaping the intravascular space — high rates of capillary permeability have been shown to be a significant prognostic marker of ICU mortality. The virus damages the capillary system, and a high leak rate is important to understanding the disease process; it can be used for triage, guide treatment and measure response to intervention giving physicians a true understanding of the status of the patient. For example, a declining leak rate would indicate that the patient is improving versus a patient with a sustained or worsening leak rate. We look forward to sharing more findings specific to COVID-19 when the data become available.

Link: Daxor Corporation homepage…





– Original Source link –


Warning: A non-numeric value encountered in /home/customer/www/myhealthyself.com/public_html/wp-content/themes/Newspaper/includes/wp_booster/td_block.php on line 353